Business · 13/08/2009Updated: 10/17/2026 · 1 min read
FDA Amends Regulation on Charging Patients for Investigational New Drugs in Clinical Trials
The Food and Drug Administration (FDA) is amending its regulation concerning charging patients for investigational new drugs in clinical trials. The final rule clarifies when charging is appropriate and sets forth criteria for charging in different expanded access scenarios.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →